PT Kimia Farma Tbk (ISX:KAEF) EBIT: Rp388,349 Mil (TTM As of Mar. 2026)


ISX:KAEF PT Kimia Farma Tbk ISX:KAEF
56 GF Score
Price Rp456.00
GF Value Rp581.98
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is PT Kimia Farma Tbk EBIT?

PT Kimia Farma Tbk ISX:KAEF -2.15% 56 EBIT is Rp388,349 Mil as of Mar. 2026. GuruFocus rates ISX:KAEF with a GF Score™ of 56/100 and a GF Value™ of Rp581.98 (Modestly Undervalued). The stock has 4 warning signs investors should review.

PT Kimia Farma Tbk's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was Rp238,110 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was Rp388,349 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PT Kimia Farma Tbk's annualized ROC % for the quarter that ended in Mar. 2026 was 1.97%. PT Kimia Farma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PT Kimia Farma Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.90%.


PT Kimia Farma Tbk  (ISX:KAEF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PT Kimia Farma Tbk's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=274449.608 * ( 1 - 3.37% )/( (14164750.425 + 12699101.548)/ 2 )
=265200.6562104/13431925.9865
=1.97 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14183178.39 - 3099263.93 - ( 377088.595 - max(0, 7060554.489 - 3979718.524+377088.595))
=14164750.425

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14358871.134 - 3434920.058 - ( 426622.403 - max(0, 6091613.427 - 4316462.955+426622.403))
=12699101.548

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

PT Kimia Farma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=952441.028/( ( (8651908.924 + max(-12468.388, 0)) + (8590473.141 + max(-41763.828, 0)) )/ 2 )
=952441.028/( ( 8651908.924 + 8590473.141 )/ 2 )
=952441.028/8621191.0325
=11.05 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1104554.043 + 1286207.058 + 1110619.965) - (3099263.93 + 0 + 414585.524)
=-12468.388

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1118500.841 + 1541995.281 + 1105334.675) - (3434920.058 + 0 + 372674.567)
=-41763.828

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PT Kimia Farma Tbk's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=388349.414/9947349.737
=3.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PT Kimia Farma Tbk EBIT Related Terms


PT Kimia Farma Tbk EBIT Historical Data

* Premium members only.

The historical data trend for PT Kimia Farma Tbk's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Kimia Farma Tbk EBIT Chart

PT Kimia Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 999,696.42 509,214.01 -1,683,294.75 -588,866.99 148,236.96

PT Kimia Farma Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,002.20 131,141.72 21,315.94 -2,218.50 238,110.26

ISX:KAEF vs MCK, COR, CAH: EBIT Comparison

For the Medical Distribution subindustry, PT Kimia Farma Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Kimia Farma Tbk EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Tbk's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PT Kimia Farma Tbk's EV-to-EBIT falls into.


ISX:KAEF
56GF Score
PT Kimia Farma Tbk ISX:KAEF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Kimia Farma Tbk EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp388,349 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of Rp388,349 Mil mean?
PT Kimia Farma Tbk (ISX:KAEF) has a EBIT of Rp388,349 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Kimia Farma Tbk.
Is PT Kimia Farma Tbk's EBIT too high?
PT Kimia Farma Tbk's current EBIT is Rp388,349 Mil. Overall, PT Kimia Farma Tbk has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Tbk's EBIT compare to MCK and COR?
PT Kimia Farma Tbk's EBIT of Rp388,349 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Kimia Farma Tbk. PT Kimia Farma Tbk's current EBIT is Rp388,349 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp581.98, compared to a current price of Rp456.00 — trading 21.6% below its estimated fair value. The current EBIT is Rp388,349 Mil. PT Kimia Farma Tbk's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For PT Kimia Farma Tbk (ISX:KAEF), the current EBIT is Rp388,349 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Kimia Farma Tbk (ISX:KAEF) Overvalued in 2026?

Based on GuruFocus' analysis, PT Kimia Farma Tbk stock appears to be undervalued. The current stock price of Rp456.00 is trading 21.6% below its estimated GF Value™ of Rp581.98. GuruFocus considers PT Kimia Farma Tbk to be Modestly Undervalued.

Key valuation signals for ISX:KAEF:

  • EBIT: Rp388,349 Mil
  • GF Value™: Rp581.98 vs. price of Rp456.00 (21.6% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Kimia Farma Tbk Business Description

Address Jalan Veteran No. 9 Gambir, Jakarta Pusat, Jakarta, IDN, 10110
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
56GF Score

Get the complete analysis for ISX:KAEF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp456.00
Price
Rp581.98
GF Value